- Home
- CNF vs ATRA Comparison
CNF vs ATRA Comparison
Compare CNF & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNF | ATRA |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9M | 38.9M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CNF | ATRA |
|---|---|---|
| Price | $4.80 | $6.29 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 5.5K | ★ 281.1K |
| Earning Date | 01-01-0001 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.93 |
| Revenue | N/A | ★ $128,940,000.00 |
| Revenue This Year | $252.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.35 |
| Revenue Growth | N/A | ★ 1404.02 |
| 52 Week Low | $0.37 | $3.92 |
| 52 Week High | $24.00 | $19.15 |
Technical Indicators
Market Signals| Indicator | CNF | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 37.84 | 54.24 |
| Support Level | $4.34 | $4.27 |
| Resistance Level | $5.48 | $13.04 |
| Average True Range (ATR) | 0.13 | 0.80 |
| MACD | -0.06 | 0.35 |
| Stochastic Oscillator | 0.00 | 70.03 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).